Clinical perspective of hypoxia-mediated pulmonary hypertension

Antioxidants and Redox Signaling

Volumn 9, Issue 6, 2007, Pages 711-721

  Preston, Ioana R ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AUTACOID; CALCIUM; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; FASUDIL; GUANOSINE TRIPHOSPHATE; IMATINIB; NITRIC OXIDE; PROSTACYCLIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN; SILDENAFIL;

ALTITUDE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; ENDOTHELIUM; FETUS CIRCULATION; HUMAN; HYPOXIA; HYPOXIC LUNG VASOCONSTRICTION; INTERSTITIAL LUNG DISEASE; LUNG BLOOD VESSEL; MITOCHONDRION; MOLECULAR MECHANICS; NONHUMAN; OXYGEN SENSING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SLEEP DISORDERED BREATHING;

ACUTE DISEASE; ANIMALS; ANOXIA; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 34249034296     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1587     Document Type: Conference Paper

References (104)

1. Executive Summary from the World Symposium on Primary Pulmonary Hypertension. Evian, World Health Organization, 1998.
2. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol 43: 1S-90S, 2004.
3. Aldashev AA, Kojonazarov BK, Amatov TA, Sooronbaev TM, Mirrakhimov MM, Morrell NW, Wharton J, and Wilkins MR. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 60: 683-687, 2005.
4. Alzamora-Castro V, Battilana G, Abugattas R, and Sialer S. Patent ductus arteriosus and high altitude. Am J Cardiol 5: 761-763, 1960.
5. Ambalavanan N, Bulger A, Murphy-Ullrich J, Oparil S, and Chen YF. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediutr Res 57: 631-636, 2005.
6. 2 sensor in rat pulmonary vasculature. Circ Res 73: 1100-1112, 1993.
7. + channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res 95: 308-318, 2004.
8. Banchero N and Cruz JC. Hemodynamic changes in the Andean native after two years at sea level. Aerosp Med 41: 849-853, 1970.
9. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, and Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 347: 436-440, 1996.
10. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, and Brundage BH, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302, 1996.
11. Bartsch P, Maggiorini M, Ritter M, Noli C, Vock P, and Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 325: 1284-1289, 1991.
12. Bindslev L, John A, Hedenstierna G, Baehrendtz S, and Santesson J. Hypoxic pulmonary vasoconstriction in the human lung: effect of repeated hypoxic challenges during anesthesia. Anesthesiology 62: 621-625, 1985.
13. 2 and cerebral blood flow in hypoxic hypoxia. Acta Physiol Scand 93: 423-432, 1975.
14. Busch T, Bartsch P, Pappert D, Grunig E, Hildebrandt W, Elser H, Falke KJ, and Swenson ER. Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am J Respir Crit Care Med 163: 368-373, 2001.
15. Carpenter T, Schomberg S, Steudel W, Ozimek J, Colvin K, Stenmark K, and Ivy DD. Endothelin B receptor deficiency pre-disposes to pulmonary edema formation via increased lung vascular endothelial cell growth factor expression. Circ Res 93: 456-463, 2003.
16. Channick RN, Hoch RC, Newhart JW, Johnson FW, and Smith CM. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am J Respir Crit Care Med 149: 811-814, 1994.
17. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, and Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79: 2122-2131, 1995.
18. Comroe JH Jr, Van Lingen B, Stroud RC, and Roncoroni A. Reflex and direct cardiopulmonary effects of 5-OH-tryptamine (serotonin); their possible role in pulmonary embolism and coronary thrombosis. Am J Physiol 173: 379-386, 1953.
19. Cornfield DN, Reeve HL, Tolarova S, Weir EK, and Archer S. Oxygen causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel. Proc Natl Acad Sci U S A 93: 8089-8094, 1996.
20. Davie NJ, Crossilo JT Jr, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter TC, Brunetti JA, McNiece IK, and Stenmark KR. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 286: L668-L678, 2004.
21. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, and Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85: 9797-9800, 1988.
22. Dorward DA, Roger Thompson AA, Kenneth Baillie J, Macdougall M, and Hirani N. Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness. Respir Med 2006.
23. Dupuis J, Stewart DJ, Cernacek P, and Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94: 1578-1584, 1996.
24. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet AS, Dartevelle P, Housset B, Hamon M, Weitzenblum E, and Adnot S. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108: 1839-1844, 2003.
25. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, and Adnot S. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 272: H1173-1181, 1997.
26. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, and McMurtry IF. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287: L656-L664, 2004.
27. Fanburg BL and Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272: L795-L806, 1997.
28. Fishman AP. State of the art: chronic cor pulmonale. Am Rev Respir Dis 114: 775-794, 1976.
29. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, and Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168: 659-669, 2006.
30. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, and Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91: 391-392, 2005.
31. Galaria H, Fegley AJ, Nicholl SM, Roztocil E, and Davies MG. Differential regulation of ERK1/2 and p38(MAPK) by components of the Rho signaling pathway during sphingosine-1-phosphate-induced smooth muscle cell migration. J Surg Res 122: 173-179, 2004.
32. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, and Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 103: 1509-1515, 1999.
33. Germann P, Ziesche R, Leitner C, Roeder G, Urak G, Zimpfer M, and Sladen R. Addition of nitric oxide to oxygen improves cardiopulmonary function in patients with severe COPD. Chest 114: 29-35, 1998.
34. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, and Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 141: 169-177, 2004.
35. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, and Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360: 895-900, 2002.
36. Groves BM, Droma T, Sutton JR, McCullough RG, McCullough RE, Zhuang J, Rapmund G, Sun S, Janes C, and Moore LG. Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m. J Appl Physiol 74: 312-318, 1993.
37. Harper AM and Glass HI. Effect of alterations in the arterial carbon dioxide tension on the blood flow through the cerebral cortex at normal and low arterial blood pressures. J Neurol Neurosurg Psychiatry 28: 449-452, 1965.
38. Hasunuma K, Rodman DM, and McMurtry IF. Effects of K+ channel blockers on vascular tone in the perfused rat lung. Am Rev Respir Dis 144: 884-887, 1991.
39. Heffner JE, Sahn SA, and Repine JE. The role of platelets in the adult respiratory distress syndrome: culprits or bystanders? Am Rev Respir Dis 135: 482-492, 1987.
40. Hultgren HN, Graver RF, and Hartley LH. Abnormal circulatory responses to high altitude in subjects with a previous history of high-altitude pulmonary edema. Circulation 44: 759-770, 1971.
41. Hultgren HN, Lopez CE, Lundberg E, and Miller H. Physiologic studies of pulmonary edema at high altitude. Circulation 29: 393-408, 1964.
42. Ivy DD, Yanagisawa M, Gariepy CE, Gebb SA, Colvin KL, and McMurtry IF. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol 282: L703-L712, 2002.
43. Jeffery TK and Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45: 173-202, 2002.
44. Jones JE, Walker JL, Song Y, Weiss N, Cardoso WV, Tuder RM, Loscalzo J, and Zhang YY. Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 286: H1775-H1784, 2004.
45. Karamsetty MR, Klinger JR, and Hill NS. Evidence for the role of p38 MAP kinase in hypoxia-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 283: L859-L866, 2002.
46. Kato M and Staub NC. Response of small pulmonary arteries to unilobar hypoxia and hypercapnia. Circ Res 19: 426-440, 1966.
47. Kawashima A, Kubo K, Kobayashi T, and Sekiguchi M. Hemodynamic responses to acute hypoxia, hypobaria, and exercise in subjects susceptible to high-altitude pulmonary edema. J Appl Physiol 67: 1982-1989, 1989.
48. Lejeune P, Mols P, Naeije R, Hallemans R, and Melot C. Acute hemodynamic effects of controlled oxygen therapy in decompensated chronic obstructive pulmonary disease. Crit Care Med 12: 1032-1035, 1984.
49. Lettieri CJ, Nathan SD, Burnett SD, Ahmad S, and Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129: 746-752, 2006.
50. Liu Q, Sham JS, Shimoda LA, and Sylvester JT. Hypoxic constriction of porcine distal pulmonary arteries: endothelium and endothelin dependence. Am J Physiol Lung Cell Mol Physiol 280: L856-L865, 2001.
51. Maclean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, and Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283: 619-624, 1997.
52. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, and Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283: 619-624, 1997.
53. Maggiolini M, Brunner-La Rocca HP, Peth S, Fischler M, Bohm T, Bernheim A, Kieneke S, Bloch KE, Dehnert C, Naeije R, Lehmann T, Bartsch P, and Mairbaurl H. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 145: 497-506, 2006.
54. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, and Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105: 1545-1547, 2002.
55. Michael JR, Kennedy TP, Buescher P, Farrukh I, Lodato R, Rock PC, Gottlieb J, Gurtner G, de la Monte SM, and Hutchins GM. Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats. Am Rev Respir Dis 133: 375-379, 1986.
56. Michelakis ED, Hampl V, Nsair A, Wu X, Harry G, Haromy A, Gurtu R, and Archer SL. Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res 90: 1307-1315, 2002.
57. + channels in smooth muscle cells by a mitochondrial redox sensor. Circ Res 91: 478-486, 2002.
58. 2-sensor in resistance artery smooth muscle cells. J Mol Cell Cardiol 37: 1119-1136, 2004.
59. Modesti PA, Vanni S, Morabito M, Modesti A, Marchetta M, Gamberi T, Sofi F, Savia G, Mancia G, Gensini GF, and Parati G. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-I (ACME-1) study. Circulation 114: 1410-1416, 2006.
60. Moinard J, Manier G, Pillet O, and Castaing Y. Effect of inhaled nitric oxide on hemodynamics and VA/Q inequalities in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 149: 1482-1487, 1994.
61. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, and Ryu JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128: 2393-2399, 2005.
62. Naeije R and MacNee W. Pulmonary circulation. In: Chronic obstructive pulmonary disease. 2nd ed. Edited by Calverely P. MacNee W, Pride P, and Rennard S. London: Arnold Health Sciences, 2003, pp. 228-242.
63. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, and Oka M. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171: 494-499, 2005.
64. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, and Oka M. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287: L665-L672, 2004.
65. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, and Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160: 600-607, 1999.
66. Penaloza D and Sime F. Circulatory dynamics during high altitude pulmonary edema. Am J Cardiol 23: 369-378, 1969.
67. Preston IR, Hill NS, Gambardella LS, Warburton RR, and Klinger JR. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood) 229: 920-925, 2004.
68. Preston IR, Hill NS, Warburton RR, and Fanburg BL. Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 290: L367-L374, 2006.
69. Reeves JT and Grover RF. Insights by Peruvian scientists into the pathogenesis of human chronic hypoxic pulmonary hypertension. J Appl Physiol 98: 384-389, 2005.
70. Riehalet JP, Gratadour P, Robach P, Pham I, Dechaux M, Joncquiert-Latarjet A, Mollard P, Brugniaux J, and Cornolo J. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 171: 275-281, 2005.
71. Robertson TP, Dipp M, Ward JP, Aaronson PI, and Evans AM. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol 131: 5-9, 2000.
72. Robertson TP, Hague D, Aaronson PI, and Ward JP. Voltage-independent calcium entry in hypoxic pulmonary vasoconstriction of intrapulmonary arteries of the rat. J Physiol 3: 669-680, 2000.
73. Roger N, Barbera JA, Roca J, Rovira I, Gomez FP, and Rodriguez-Roisin R. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156: 800-806, 1997.
74. Rudolph AM. Circulatory adjustments after birth: effects on ventricular septal defect. Br Heart J 33(suppl): 32-34, 1971.
75. Rupert JL and Koehle MS. Evidence for a genetic basis for altitude-related illness. High Alt Med Biol 7: 150-167, 2006.
76. Sajkov D, Wang T, Saunders NA, Bune AJ, and McEvoy RD. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 165: 152-158, 2002.
77. Sartori C, Vollenweider L, Loffler BM, Delabays A, Nicod P, Bartsch P, and Scherrer U. Exaggerated endothelin release in high-altitude pulmonary edema. Circulation 99: 2665-2668, 1999.
78. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, and Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166: 314-322, 2002.
79. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, and Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005.
80. Scherrer U, Sartori C, Lepori M, Allemann Y, Duplain H, Trueb L, and Nicod P. High-altitude pulmonary edema: from exaggerated pulmonary hypertension to a defect in transepithelial sodium transport. Adv Exp Med Biol 474: 93-107, 1999.
81. Scherrer U, Vollenweider L, Delabays A, Savcic M, Eichenberger U, Kleger GR, Fikrle A, Ballmer PE, Nicod P, and Bartsch P. Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 334: 624-629, 1996.
82. Schoeffter P, Lugnier C, Demesy-Waeldele F, and Stoclet JC. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta: a study with selective inhibitors. Biochem Pharmacol 36: 3965-3972, 1987.
83. Schoene RB, Swenson ER, Pizzo CJ, Hackett PH, Roach RC, Mills WJ Jr, Henderson WR Jr. and Martin TR. The lung at high altitude: bronchoalveolar lavage in acute mountain sickness and pulmonary edema. J Appl Physiol 64: 2605-2613, 1988.
84. Sebkhi A, Strange JW, Phillips SC, Wharton J, and Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107: 3230-3235, 2003.
85. Shibuya M, Asano T, and Sasaki Y. Effect of fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm. Acta Neurochir Suppl 77: 201-204, 2001.
86. Shivkumar K, Ravi K, Henry JW, Eichenhorn M, and Stein PD. Right ventricular dilatation, righi ventricular wall thickening, and Doppler evidence of pulmonary hypertension in patients with a pure restrictive ventilatory impairment. Chest 106: 1649-1653, 1994.
87. Sime F, Banchero N, Penaloza D, Gamboa R, Cruz J, and Marticorena E. Pulmonary hypertension in children born and living at high altitudes. Am. J Cardiol 11: 143-149, 1963.
88. Sime F, Penaloza D, and Ruiz L. Bradycardia, increased cardiac output, and reversal of pulmonary hypertension in altitude natives living at sea level. Br Heart J 33: 647-657, 1971.
89. Szaszi K, Sirokmany G, Di Ciano-Oliveira C, Rotslein OD, and Kapus A. Depolarization induces Rho-Rho kinase-mediated myosin light chain phosphorylation in kidney tubular cells. Am J Physiol Cell Physiol 289: C673-C685, 2005.
90. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, and Mal H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127: 1531-1536, 2005.
91. Timms RM, Khaja FU, and Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 102: 29-36, 1985.
92. Tristani-Firouzi M, Reeve HL, Tolarova S, Weir EK, and Archer SL. Oxygen-induced constriction of rabbit ductus arteriosus occurs via inhibition of a 4-aminopyridine-, voltage-sensitive potassium channel. J Clin Invest 98: 1959-1965, 1996.
93. Tucker A, Migally N, Wright ML, and Greenlees KJ. Pulmonary vascular changes in young and aging rats exposed to 5,486 m altitude. Respiration 46: 246-257, 1984.
94. Tucker A and Reeves JT. Nonsustained pulmonary vasoconstriction during acute hypoxia in anesthetized dogs. Am J Physiol 228: 756-761, 1975.
95. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, and Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994, 1997.
96. Von Euler U and Liljestrand G. Observations on the pulmonary arterial blood pressure of the cat. Acta Physiol Scand 12: 301-320, 1946.
97. Wagenvoort CA and Wagenvoort N. Pulmonary venous changes in chronic hypoxia. Virchows Arch A Pathol Anat Histol 372: 51-56, 1976.
98. Waypa GB, Chandel NS, and Schumacker PT. Model for hypoxic pulmonary vasoconstriction involving mitochondrial oxygen sensing. Circ Res 88: 1259-1266, 2001.
99. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, and Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 130: 993-998, 1984.
100. West JB. The physiologic basis of high-altitude diseases. Ann Intern Med 141: 789-800, 2004.
101. West JB and Mathieu-Costello O. Structure, strength, failure, and remodeling of the pulmonary blood-gas barrier. Annu Rev Physiol 61: 543-572, 1999.
102. Wood JG, Johnson JS, Mattioli LF, and Gonzalez NC. Systemic hypoxia increases leukocyte emigration and vascular permeability in conscious rats. J Appl Physiol 89: 1561-1568, 2000.
103. Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Noguchi Y, Sudoh K, Sasamata M, and Miyata K. A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats. Vascul Pharmacol 43: 40-46, 2005.
104. Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, and Palasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 113: 65-70, 1998. Address reprint requests to: